Reltecimod (NSC-37096; AB-103; P-2TA) is a novel and potent CD28 antigen inhibitor with the potential for the treatment of necrotizing soft tissue infection. As a T-cell-specific surface glycoprotein CD28 (TP44) antagonist, Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it.

纯度：≥98%

CAS：1447799-33-8